Long Noncoding RNA H19: A Key Player in Liver Diseases

Yanyan Wang,Phillip B. Hylemon,Huiping Zhou
DOI: https://doi.org/10.1002/hep.31765
IF: 17.298
2021-08-30
Hepatology
Abstract:<p>The rapid advance in deep sequencing technologies has identified numerous long non‐coding RNAs (lncRNA) and their biological functions are increasingly being recognized as important regulators of gene expression and cell signaling pathways. H19 is the first lncRNA identified and characterized as the first imprinted gene in the pre‐genomic era. During the last three decades, H19 has been extensively investigated as a multitasking lncRNA. H19 plays a crucial role in regulating many biological functions and is intimately involved in the pathogenesis of various human diseases. Here, we highlight the recent findings related to H19 in liver diseases. The unique features of H19 biogenesis and regulation make it an attractive diagnostic and prognostic biomarker and potential therapeutic target for certain liver diseases. Conclusions: The roles of H19 in liver disease remains obscure. The rapid advance in new technologies offers promise for the understanding of the mechanisms of lncRNA H19 in physiological and pathological processes of liver diseases and for the development novel therapeutics.</p>
gastroenterology & hepatology
What problem does this paper attempt to address?
This paper primarily explores the role of long non-coding RNA H19 in liver diseases, particularly its functions in non-alcoholic fatty liver disease (NAFLD), cholestatic liver disease, and hepatocellular carcinoma (HCC). ### Non-Alcoholic Fatty Liver Disease (NAFLD) - **Background**: NAFLD is a global health issue closely related to the prevalence of obesity. Currently, there is a lack of reliable diagnostic markers and approved drugs for treatment. - **Role of H19**: Studies have found that H19 promotes lipid accumulation by regulating the stability of genes related to lipidogenesis or by inhibiting specific microRNAs (such as miR130a). Additionally, H19 can participate in the development of NAFLD by affecting other pathways. ### Cholestatic Liver Disease - **Background**: Cholestatic liver disease is a group of diseases that cause bile flow obstruction, including primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC) in adults. - **Role of H19**: H19 plays a crucial role in cholestatic liver injury by acting as a sponge for microRNAs, thereby influencing multiple signaling pathways and activating various cell types such as macrophages, cholangiocytes, and hepatic stellate cells. ### Hepatocellular Carcinoma (HCC) - **Background**: HCC is the most common primary liver cancer, usually diagnosed at a late stage. - **Role of H19**: The role of H19 in HCC is complex; it can act as both an oncogene and a tumor suppressor, depending on the different microRNAs, RNA-binding proteins, and signaling pathways it regulates. Although H19 is abnormally upregulated in various types of cancer, its specific role in HCC remains controversial. ### Conclusion and Future Prospects - Due to its extensive functions, H19 has garnered increasing attention in both physiological and pathological processes. Although H19 was discovered over 30 years ago, its exact role in liver diseases remains unclear. - Recent studies have strengthened the view of H19 as a novel diagnostic and prognostic biomarker and suggested that H19 could be a potential target for liver disease treatment. - Researchers need to conduct more mechanistic and translational studies to validate the efficacy of H19 as a novel therapeutic target for liver diseases.